EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Pre‐Clinical Development of Two DNA Vaccines Encoding MrkA of Klebsiella pneumoniae : Effect of Plasmid Backbone on Immunogenicity and Protective Efficacy Against Sepsis

Marta Vicente-Pazos iD, Estéfani García-Ríos iD, Laura Quílez-Agraz iD, Gal la Ustrell-Sallent iD, Pilar Pérez-Romero iD, Mireia López-Siles iD, Michael J McConnell iD

Microbial Biotechnology · 2026

DOI: 10.1111/1751-7915.70434 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Microbial Biotechnology, 2026. Verfasst von Marta Vicente-Pazos und 6 weiteren Autor:innen. Beteiligte Einrichtung: Intrahospital Infections Laboratory, National Centre for Microbiology, Instituto de Salud Carlos III (ISCIII), Madrid, Spain. Hauptthemen laut MEDLINE: Vaccines, DNA, Klebsiella pneumoniae, Plasmids, Klebsiella Infections. Die Arbeit nennt 98 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Instituto de Salud Carlos III, Generalitat Valenciana, Fundació "la Caixa".

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Development of vaccines against Klebsiella pneumoniae has potential to prevent infections in both community and hospital settings and reduce associated mortality and morbidity worldwide. DNA vaccines represent a promising approach given their stability, safety, design flexibility and cost‐effectiveness for rapid production. In this study, two plasmid backbones, namely the commercial pVAX1 and the newly designed PLASMIVAX (containing additional CpG motifs), were tested to develop two DNA vaccines targeting the MrkA fimbrial subunit from K. pneumoniae . MrkA is highly conserved among K. pneumoniae and was expressed and secreted in vitro, fused to immunostimulatory elements, by both DNA vaccines following transfection of HEK‐293T cells. Immunogenicity was assessed in mice by measuring antibody levels (IgM, IgG, IgG1, IgG2a and IgG3) after intramuscular immunization with three doses of 50 μg of each DNA vaccine. Efficacy of protection was established in a sepsis infection model. The pVAX1‐MrkA DNA vaccine elicited the most robust antibody response and protection against K. pneumoniae infection (80%, p = 0.0373), while the PLASMIVAX‐MrkA DNA vaccine protected at a lower rate (30%, p = 0.0163), consistent with lower post‐immunization antibody titers elicited by this vaccine. This study reveals that DNA plasmid properties strongly influence immunogenicity and vaccine efficacy and highlights the potential role of MrkA as a vaccine antigen and DNA platforms as a valuable tool for developing vaccines against multidrug‐resistant bacteria.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Vaccines, DNAKlebsiella pneumoniaePlasmidsKlebsiella InfectionsSepsisBacterial VaccinesBacterial ProteinsAnimalsAntibodies, BacterialHumansMiceFemaleDisease Models, AnimalMice, Inbred BALB CHEK293 CellsImmunoglobulin GImmunogenicity, Vaccine

Stichwörter der Autor:innen

Klebsiella pneumoniaeDNA vaccinemultidrug resistanceplasmid backbonevaccine

Substanzen

Vaccines, DNAAntibodies, BacterialBacterial VaccinesBacterial ProteinsImmunoglobulin G

Autor:innen und Institutionen

  • Intrahospital Infections Laboratory, National Centre for Microbiology, Instituto de Salud Carlos III (ISCIII), Madrid, Spain.
  • Doctoral Program in Biomedical Sciences and Public Health, IMIENS, Universidad Nacional de Educación a Distancia (UNED), Madrid, Spain.
  • Microbiology of Intestinal Diseases, Department of Biology, Universitat de Girona, Girona, Spain.
  • Instituto de Ciencias de la Vida y del Vino (CSIC, Universidad de La Rioja, Gobierno de La Rioja), Logroño, Spain.
  • Department of Biological Sciences, University of Notre Dame, Notre Dame, Indiana, USA.
  • Eck Institute for Global Health, Notre Dame, Indiana, USA.

ORCID-Profile: Marta Vicente-Pazos, Estéfani García-Ríos, Laura Quílez-Agraz, Gal la Ustrell-Sallent, Pilar Pérez-Romero, Mireia López-Siles, Michael J McConnell

Förderung

  • Instituto de Salud Carlos III
  • Generalitat Valenciana
  • Fundació "la Caixa"
  • Agència de Gestió d'Ajuts Universitaris i de Recerca

Zitieren

APA

Vicente-Pazos, M., García-Ríos, E., Quílez-Agraz, L., Ustrell-Sallent, G., Pérez-Romero, P., López-Siles, M., & McConnell, M. J. (2026). Pre‐Clinical Development of Two DNA Vaccines Encoding MrkA of Klebsiella pneumoniae : Effect of Plasmid Backbone on Immunogenicity and Protective Efficacy Against Sepsis. Microbial Biotechnology. https://doi.org/10.1111/1751-7915.70434

Vancouver

Vicente-Pazos M, García-Ríos E, Quílez-Agraz L, Ustrell-Sallent G, Pérez-Romero P, López-Siles M, et al. Pre‐Clinical Development of Two DNA Vaccines Encoding MrkA of Klebsiella pneumoniae : Effect of Plasmid Backbone on Immunogenicity and Protective Efficacy Against Sepsis. Microbial Biotechnology. 2026. doi:10.1111/1751-7915.70434

BibTeX
@article{VicentePazos2026,
  author = {Vicente-Pazos, Marta and García-Ríos, Estéfani and Quílez-Agraz, Laura and Ustrell-Sallent, Gal la and Pérez-Romero, Pilar and López-Siles, Mireia and McConnell, Michael J},
  title = {Pre‐Clinical Development of Two DNA Vaccines Encoding MrkA of Klebsiella pneumoniae : Effect of Plasmid Backbone on Immunogenicity and Protective Efficacy Against Sepsis},
  journal = {Microbial Biotechnology},
  year = {2026},
  doi = {10.1111/1751-7915.70434}
}
Kostenlos starten →